Navigation Links
MEI Pharma to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:9/17/2013

ients with solid refractory tumors are anticipated in October 2013. In September 2013, the Company further expanded its pipeline of drug candidates with the acquisition of PWT143, a highly selective PI3-kinase delta inhibitor. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-t
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a North ... an online store to add customer convenience in ... and manufactured by Biological Industries, Inc. , Products ... Nutristem® serum-free, xeno-free reagents for human mesenchymal stem ... culture. , The online store also offers ...
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... DIEGO, June 1, 2011 BioSurplus today announced it will be ... Alto / San Francisco Bay area and the second a campus-wide ... the auctions can be found on the BioSurplus auction site at ... Area Auction Details Over 1200 items are available ...
... 1, 2011 Selexis SA, a Swiss-based biotechnology ... engineering of high yield and stable mammalian cell ... announced today representatives from the Company will be ... Partnering Meetings being held Jun 27-30 in Washington, ...
... The creation of a new quasiparticle called the ... to integrated photonic circuits and optical computing for ... of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... for next generation on-chip optical communication systems. ...
Cached Biology Technology:BioSurplus to Host Two of the Largest Biotech Auctions Ever 2Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC 2Nanoscale waveguide for future photonics 2Nanoscale waveguide for future photonics 3Nanoscale waveguide for future photonics 4
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
(Date:9/29/2014)... planetary geologists have speculated that glaciers might once ... that constitutes the Grand Canyon of Mars. Using ... have been carved by past glaciers as they ... remained highly controversial and contested. , Now, ... the Freie Universitaet Berlin has identified what could ...
(Date:9/29/2014)... beginning of the age of dinosaurs, gigantic reptilesdistant relatives ... and others in water and it was thought they ... University of Tennessee, Knoxville, researcher in the thigh of ... , Stephanie Drumheller, an earth and planetary sciences ... Sterling Nesbitt examined 220-million-year-old bite marks in the thigh ...
Breaking Biology News(10 mins):New VCU center to target cocaine addiction 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9Tooth serves as evidence of 220 million-year-old attack 2
... A prototype drug created by researchers at the University ... of the virus responsible for severe acute respiratory syndrome, ... agents or vaccines for SARS, which killed almost 800 ... basis of their success, the researchers have received an ...
... of malaria is in prospect with a clinical drug trial ... in the trial would open the way to relief in ... fatal disease - over 500,000,000 people. , The Walter ... the Papua New Guinea Institute of Medical Research (PNGIMR) and ...
... research ?including research involving human embryonic stem cells ?is ... a position statement adopted by the Board of Directors ... the community of scientists on the front lines of ... belief that continued experimentation with human stem cells is ...
Cached Biology News:UIC developing drug for SARS 2UIC developing drug for SARS 3Old drug, new tricks: Prospects for slashing the impact of malaria 2AACR Favors 'full spectrum of stem cell research biology' 2AACR Favors 'full spectrum of stem cell research biology' 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: